Metastasis in renal cell carcinoma: Biology and treatment

被引：5
作者：
Kanwal, Rafiah [1 ]
机构：
[1] Univ Management & Technol, Dept Life Sci, Lahore, Pakistan
来源：
ADVANCES IN CANCER BIOLOGY-METASTASIS | 2023年 / 7卷
关键词：
Renal cell carcinoma; Bone metastasis; Adrenal metastasis; Brain metastasis; Pancreas metastasis; Gallbladder metastasis; VEGF; mTOR; TRANSFORMING-GROWTH-FACTOR; HORMONE-RELATED PROTEIN; BLIND PHASE-III; INTERFERON-ALPHA; RADICAL NEPHRECTOMY; CYTOREDUCTIVE NEPHRECTOMY; GALLBLADDER METASTASIS; PANCREATIC METASTASES; PROGNOSTIC-FACTORS; TARGETED THERAPY;
D O I：
10.1016/j.adcanc.2023.100094
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Renal cell carcinoma (RCC) is a heterogeneous group of cancer that reacts inappropriately to recent therapeutic methods and is frequently linked with an uncertain clinical channel. The biology of renal cell carcinoma (RCC) depends on histology, tumor diversity, and the biological mechanism of metastasis. Malignant renal cell carcinoma (RCC) tumors can spread to bones, brain, pancreas, gallbladder, and adrenal gland resulting in metastasis. Medical treatment for renal cell carcinoma (RCC) has transformed from cytokine-based methods to targeted agent therapy against vascular endothelial growth factor (VEGF), and most recently to immunotherapy drugs. This review aims to summarize the biology of renal cell carcinoma and to understand the present and future directions in the treatment of metastasis.
引用
收藏
页数：7
相关论文
共 133 条
[1]   Safety and efficacy of nivolumab in combination with sunitinib or pazopanib in advanced or metastatic renal cell carcinoma: the CheckMate 016 study [J].
Amin, Asim ;
Plimack, Elizabeth R. ;
Ernstoff, Marc S. ;
Lewis, Lionel D. ;
Bauer, Todd M. ;
McDermott, David F. ;
Carducci, Michael ;
Kollmannsberger, Christian ;
Rini, Brian I. ;
Heng, Daniel Y. C. ;
Knox, Jennifer ;
Voss, Martin H. ;
Spratlin, Jennifer ;
Berghorn, Elmer ;
Yang, Lingfeng ;
Hammers, Hans J. .
JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2018, 6
[2]   Everolimus versus sunitinib for patients with metastatic non-clear-cell renal cell carcinoma (ASPEN): a multicentre, open-label, randomised phase 2 trial [J].
Armstrong, Andrew J. ;
Halabi, Susan ;
Eisen, Tim ;
Broderick, Samuel ;
Stadler, Walter M. ;
Jones, Robert J. ;
Garcia, Jorge A. ;
Vaishampayan, Ulka N. ;
Picus, Joel ;
Hawkins, Robert E. ;
Hainsworth, John D. ;
Kollmannsberger, Christian K. ;
Logan, Theodore F. ;
Puzanov, Igor ;
Pickering, Lisa M. ;
Ryan, Christopher W. ;
Protheroe, Andrew ;
Lusk, Christine M. ;
Oberg, Sadie ;
George, Daniel J. .
LANCET ONCOLOGY, 2016, 17 (03) :378-388
[3]   MUC1, a New Hypoxia Inducible Factor Target Gene, Is an Actor in Clear Renal Cell Carcinoma Tumor Progression [J].
Aubert, Sebastien ;
Fauquette, Valerie ;
Hemon, Brigitte ;
Lepoivre, Rejane ;
Briez, Nicolas ;
Bernard, David ;
Van Seuningen, Isabelle ;
Leroy, Xavier ;
Perrais, Michael .
CANCER RESEARCH, 2009, 69 (14) :5707-5715
[4]   Treatment of renal cell carcinoma: Current status and future directions [J].
Barata, Pedro C. ;
Rini, Brian I. .
CA-A CANCER JOURNAL FOR CLINICIANS, 2017, 67 (06) :507-524
[5]   High recurrence rate after atypical resection for pancreatic metastases from renal cell carcinoma [J].
Bassi, C ;
Butturini, G ;
Falconi, M ;
Sargenti, M ;
Mantovani, W ;
Pederzoli, P .
BRITISH JOURNAL OF SURGERY, 2003, 90 (05) :555-559
[6]  
Belldegrun AS, 2013, J CLIN ONCOL, V31
[7]  
BENNINGT.JL, 1973, CANCER, V32, P1017, DOI 10.1002/1097-0142(197311)32:5<1017::AID-CNCR2820320501>3.0.CO
[8]  
2-Z
[9]   CEREBRAL NEOPLASMS INITIALLY PRESENTING WITH MASSIVE INTRACEREBRAL HEMORRHAGE [J].
BITOH, S ;
HASEGAWA, H ;
OHTSUKI, H ;
OBASHI, J ;
FUJIWARA, M ;
SAKURAI, M .
SURGICAL NEUROLOGY, 1984, 22 (01) :57-62
[10]  
Bucci L, 1986, Riv Neurol, V56, P325
12345678910